// changes done below on July 01 2024 // till here on July 01 2024

Oral Proteins and Peptides Market Revenue to Cross USD 8.4 Billion by 2032 | Roots Analysis

Published: February 2024


According to a recently published report by Roots Analysis, the growing prevalence of chronic diseases, the surge in patient preference for oral therapeutic drugs, and improved patient compliance are anticipated to drive the oral proteins and peptides market.

Global Oral Proteins and Peptides Market Overview

The global oral protein and peptide market is anticipated to grow at a CAGR of 20% from 2023-2032, reaching USD 8.4 billion by 2032.

Oral proteins are a form of pharmaceutical drugs formulated to be administered orally by patients. These types of drugs are in great demand for treating a wide range of disease indications across different therapeutic areas. Patients suffering from chronic diseases require frequent doses of drugs to manage their conditions. Previously, the majority of the drugs have been delivered to the patients subcutaneously, which is painful and difficult for the patients. Oral proteins and peptide drug formulations emerge as a viable solution for patients to get their doses without having intravenous injections. It is interesting to note here that over three proteins and peptide-based drugs have been approved by the FDA, including Mycapssa® (2020), Trulance® (2017), and Linzess® (2012). Increasing technological advancements, growing preferences for oral drugs, and rising approval from the regulatory authorities have facilitated the production of these drugs. Owing to its non-invasive approach, oral proteins, and peptide-based drugs improved patient compliance, which is anticipated to become the major growth driver propelling the market during the forecast period.

The 481-page report contains a detailed Table of Contents on "Oral Protein and Peptide Market," Target Disease Indication, Type of Molecule, Technology Platforms, Biological Target, Mechanism of Action, Key Players and Global Forecasts, 2023-2032” here: https://www.rootsanalysis.com/reports/oral-proteins-and-peptides-market/192.html

Market Drivers

The rising prevalence of chronic diseases such as gastrointestinal disorders and metabolic disorders has led to the development of oral proteins and peptide-based drugs, which are anticipated to drive the market. The ongoing innovations in drug delivery technologies, particularly for the emerging oral delivery systems, increase these drugs' bioavailability and stability. Furthermore, the increasing preference for oral drug formulation over traditional drug delivery approaches for managing chronic diseases has become a primary growth factor driving the market during the forecast period.

Market Restraints

Despite the significant growth drivers, the low bioavailability of the oral proteins and peptide-based therapeutic drugs restrict the use of these substances for treatment. The high cost of producing oral proteins and peptide-based drugs may impede market growth, especially for small companies.

Growth Factors

The rising interest of pharmaceutical companies in the development of oral proteins and peptides-based therapeutics provides enormous growth opportunities in this field. Further, the flexibility provided by regulatory bodies to support the development of oral protein and peptide-based drugs has contributed to the market's growth. The rising awareness about healthcare and the emergence of economies for the development of infrastructure that supports the production of oral proteins-based drugs are the key growth factors driving the market in the future.

Oral Proteins and Peptides Market Segments

Based on the target disease indication, the oral proteins and peptides market is segmented into acromegaly, celiac disease, chronic idiopathic constipation, enteric hyperoxaluria, inflammatory bowel disease, and type II diabetes

  • Based on the target disease indication, Type II diabetes will dominate the oral proteins and peptides market and is estimated to hold 46.9% of the overall revenue share by 2032.
  • Type II diabetes is anticipated to grow at a higher CAGR of 83.01% during the forecast period.

Based on the type of molecules, the oral proteins and peptides market is segmented into protein and peptides.

  • Peptide molecules will dominate the oral proteins and peptides market and are anticipated to capture 69.27% of the overall share by 2032.
  • Protein molecules will grow at a higher CAGR of 92% during the forecast period.

Based on the type of biological targets, the oral proteins and peptides market is segmented into GC-C, insulin receptor, oxalate, and others

  • Based on the type of biological targets, the market is dominated by other targets, holding 38.58% of revenue share by 2032.
  • Other biologics targets will likely grow at a higher CAGR of 37.83% during the forecast period.

Based on the mechanism of action, the oral proteins and peptides market is segmented into receptor stimulation, substrate degradation, and others.

  • The receptor stimulation dominates the oral proteins and peptides market and is poised to capture 56.73% by 2032.
  • Other mechanisms of action will grow at a higher compounded annual growth rate (CAGR) of 39.21% during the forecast period.

Key Technologies Platform

The oral proteins and peptides market report also includes the key technologies platforms offered by the leading players, including:

  • Axcess™ Oral Drug Delivery Technology (Proxima Concepts)
  • Eligen™ Technology (Emisphere Technologies)
  • Entera Technology  (Entera Bio)
  • NTRA Oral Delivery Technology (Nutrinia)
  • Peptelligence® Technology (Enteris BioPharma)
  • Protein Oral Delivery (POD™) Technology (Oramed Pharmaceuticals)
  • Transient Permeability Enhancer (TPE®) Technology (Chiasma Pharma)
  • Uroguanylin Analogue Technology (Synergy Pharmaceuticals)

You Can Download Free Sample PDF Copy of This Report At:
https://www.rootsanalysis.com/reports/oral-proteins-and-peptides-market/request-sample.html

Don’t Miss Out on Other Interesting Titles:

  1. Oral Solid Dosage Manufacturing Market
  2. Intravenous Immunoglobulin Manufacturing Market
  3. Probiotics Market
  4. Antibody Discovery Market

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists, and strategic investors for over a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serving our clients in the best possible way.

Contact US
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com
Website: https://www.rootsanalysis.com

MEDIA CITATIONS

  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry